360° SearchNetwork Hot Spots Trends Time Series

taxane

Type: Keyphrase

Name: taxane

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Caspase-2 is involved in cell death induction by taxanes in breast cancer cells

We studied the role of caspase-2 in apoptosis induction by taxanes (paclitaxel, novel taxane SB-T-1216) in breast cancer cells using SK-BR-3 (nonfunctional p53, functional caspase-3) and MCF-7 (functional p53, nonfunctional caspase-3) cell lines.Results: ... [Published 7thSpace - May 15 2013]

Entities: taxane, Breast Cancer, Cell Lines

First reported May 08 2013 - Updated May 08 2013 - 1 reports

University of Washington

Researchers from University of Washington Report New Studies. . .

Researchers from University of Washington Report New Studies and Findings in the Area of Prostate CancerProstate CancerNewsRx.comBy a News Reporter-Staff News Editor at Cancer Vaccine Week -- Research findings on Prostate Cancer are discussed in a new ... [Published Equities.com - May 08 2013]

Entities: University of Washington, docetaxel, Prostate Cancer, Urology

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Taxane benefit in breast cancera role for grade and chromosomal stability

Home » Syndicated Content » Taxane benefit in breast cancer—a role for grade and chromosomal stabilityIn this Perspectives article, the authors propose that lower histological grade in breast cancer might be a hallmark of relative chromosomal stability, ... [Published BioPortfolio - May 07 2013]

Entities: taxane, Breast Cancer, Biotechnology, Consortium

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Eisai Co Ltd

Eisai Files for Earlier use of Halaven (Eribulin) for the Treatment of Metastatic Breast Cancer

/PRNewswire/ --ï»¿Eisai today announced that it has filed a Type II Variation application with the European Medicines Agency (EMA) for Halaven (eribulin), requesting an indication extension to include treatment of earlier line metastatic breast cancer ... [Published FinanzNachrichten.de - May 07 2013]

Entities: Eribulin, Eisai Co Ltd, Metastatic, Halaven, Breast Cancer

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Herceptin

Kadcyla Safety Alert

2013The FDA has notified health care providers that the use of the incorrect generic name for Genentechâs Kadcyla (ado-trastuzumab emtansine) in some medication-related electronic systems poses a risk of confusion with Genentechâs Herceptin (trastuzumab), ... [Published Facts & Comparisons - May 07 2013]

Entities: Kadcyla, Herceptin, human epidermal growth factor receptor 2, taxane

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Cabazitaxel: A guide to its use in hormone-refractory metastatic prostate cancer - Abstract

The taxane derivative cabazitaxel (Jevtana(®)) is approved in the USA and the EU for use in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing re ... [Published UroToday - May 06 2013]

Entities: Cabazitaxel, Metastatic, Prostate Cancer

First reported Apr 09 2013 - Updated Apr 10 2013 - 1 reports

Eddingpharm, GSK in Commercialization Pact

Related Searches: Collaborations & Alliances • Pharma • • Development •Related Breaking NewsEddingpharm, a specialty pharma company in China, has entered into a collaboration agreement with GlaxoSmithKline China, to acquire exclusive rights in China to ... [Published Contract Pharma - Apr 09 2013]

Entities: Tykerb, China State Food & Drug Administration, China, Metastatic

First reported Feb 25 2013 - Updated Feb 26 2013 - 1 reports

Breakthrough In Breast Cancer Treatment Could Increase Life Expectancy, Reduce Side Effects

A breakthrough in cancer treatment could potentially have a big impact on the 1 in 8 women who are diagnosed with breast cancer at some point in their lives. The New York Times reports that the Food and Drug Administration (FDA) has approved ... [Published Think Progress - Feb 25 2013]

Entities: Kadcyla, Breast Cancer, Herceptin, Drugs

First reported Feb 22 2013 - Updated Feb 23 2013 - 1 reports

4 Healthcare Stock Stories Prescribed for Weekend Reading

Vivus ( NASDAQ:VVUS ): Current price $12.36 Vivus announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use has confirmed its October 18th decision to decline the Marketing Authorization Application for ... [Published Wall St. Cheat Sheet - Feb 22 2013]

Entities: ImmunoGen Inc, Kadcyla, Lyrica

First reported Feb 14 2013 - Updated Feb 14 2013 - 1 reports

ImmunoGen, Surprisingly Quiet Ahead Of FDA Decision

By Brian L. Wilson : Immunogen (NASDAQ: IMGN ) , one of the better performing cancer drug plays this year (up 14.4% since the start of the year), has quite a bit on its plate for 2013. The most immediate and pressing catalyst is the PDUFA action ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 14 2013]

Entities: ImmunoGen Inc, Herceptin, GASTRIC CANCER

First reported Jan 11 2013 - Updated Jan 11 2013 - 2 reports

Results from Morphoteks farletuzumab Phase III combination study on ovarian cancer

Morphotek Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive ep.. ... [Published BioPortfolio - Jan 11 2013]

Entities: farletuzumab, Phase III, Ovarian Cancer

Quotes

...population where there remains an unmet need," said Alessandro Riva, Global Head, Oncology Development & Medical Affairs, Novartis Oncology. "Everolimus works differently than any currently available treatment for HER2 positive breast cancer, and these results support its potential expanded role in advanced breast cancer."

Novartis drug Afinitor® significantly extended time without disease progression in women with HER ... [Published Quoteline - May 17 2013]

Mr. Junius continued, "While we are highly excited about Kadcyla, we believe even greater value for our shareholders will come from our wholly owned compounds. Patient enrollment is going well in our IMGN901, IMGN853, and IMGN529 clinical trials, and we are on track to advance our next compound, IMGN289, into the clinic later this year. Each of these compounds is highly differentiated and has the potential to become an important therapy for cancers that need better treatment options." Product Pipeline Update Kadcyla (ado-trastuzumab emtansine, previously T-DM1) is a HER2-targeting product with ImmunoGen's TAP technology that is being...

ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly U ... [Published Pharmacy Choice - May 13 2013]

According to the news reporters, the research concluded: "Further understanding of the microtubule-dependent HIF-1a regulation, and lack thereof in RCC, is essential given the importance of HIF-1a in tumor biology, and the widespread use of MTDs in clinical oncology."

Cytoskeleton: Research Conducted at Cornell University College of Medicine Has Updated Our Knowle ... [Published NewsRX - May 10 2013]

According to the news reporters, the research concluded: "With multiple life-prolonging agents available, it now becomes imperative to coordinate how and when these new therapies should be used and sequenced to achieve optimal patient outcomes."

Researchers from University of Washington Report New Studies. . . [Published Equities.com - May 08 2013]

More Content

sort by: Date \| Relevance
Novartis Says BOLERO-3 Study On Afinitor Meets ... [Published RTTNews.com - 22 hours ago]
Novartis drug Afinitor® significantly extended ... [Published Quoteline - May 17 2013]
Novartis drug Afinitor® significantly extended ... [Published TD Ameritrade - May 17 2013]
Caspase-2 is involved in cell death induction b... [Published 7thSpace - May 15 2013]
ImmunoGen, Inc. Reports Third Quarter Fiscal Ye... [Published Pharmacy Choice - May 13 2013]
ImmunoGen's Management Presents at Credit Suiss... [Published Seeking Alpha - May 12 2013]
Celldex Therapeutics' Management Presents at Cr... [Published Seeking Alpha - May 11 2013]
Cytoskeleton: Research Conducted at Cornell Uni... [Published NewsRX - May 10 2013]
Researchers from University of Washington Repor... [Published Equities.com - May 08 2013]
Taxane benefit in breast cancera role for grade... [Published BioPortfolio - May 07 2013]
HA, CPSS, EDGW, SNY, ASTM, UACL Are Seasonally ... [Published TradingCharts.com - May 07 2013]
Kadcyla Safety Alert [Published Facts & Comparisons - May 07 2013]
Eisai Files for Earlier use of Halaven (Eribuli... [Published FinanzNachrichten.de - May 07 2013]
Kadcyla (ado-trastuzumab emtansine): Drug Safet... [Published U.S. Food and Drug Administration - May 06 2013]
Cabazitaxel: A guide to its use in hormone-refr... [Published UroToday - May 06 2013]
GTx Inc.'s CEO Discusses Q1 2013 Results - Earn... [Published Seeking Alpha - May 03 2013]
ImmunoGen Posts 3rd Quarter Fiscal Year 2013 Fi... [Published Individual.com - May 01 2013]
Active Runners - Genta Incorporated (OTCMKTS:GN... [Published SBWire - Apr 30 2013]
Olaparib: a promising PARP inhibitor in ovarian... [Published BioPortfolio - Apr 27 2013]
Recent Findings from Orebro University Hospital... [Published Equities.com - Apr 25 2013]
Media Release Interim Report as of March 31, 2013 [Published Noodls - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Yahoo! Finance - Apr 18 2013]
BB BIOTECH AG: Biotech sector maintains upward ... [Published FinanzNachrichten.de - Apr 18 2013]
BB BIOTECH AG : Biotech sector maintains upward... [Published Investegate - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Zecco - Apr 18 2013]
Survey: Nearly Two-Thirds of Ovarian Cancer Pat... [Published Oncology Times - Apr 18 2013]
Patent Issued for Pharmaceutical Compositions C... [Published Equities.com - Apr 17 2013]
Eddingpharm to acquire Tykerb rights from Glaxo... [Published Pharmaceutical Business Review - Apr 10 2013]
GSK licenses out Tykerb in China, signs Singapo... [Published Pharma Times - Apr 10 2013]
Eddingpharm, GSK in Commercialization Pact [Published Contract Pharma - Apr 09 2013]

Blogs

sort by: Date \| Relevance
Breakthrough In Breast Cancer Treatment Could I... [Published Think Progress - Feb 25 2013] A breakthrough in cancer treatment could potentially have a big impact on the 1 in 8 women who are diagnosed with breast cancer at some point in their lives. The New York Times reports that the Food and Drug Administration (FDA) has approved ...
4 Healthcare Stock Stories Prescribed for Weeke... [Published Wall St. Cheat Sheet - Feb 22 2013] Vivus ( NASDAQ:VVUS ): Current price $12.36 Vivus announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use has confirmed its October 18th decision to decline the Marketing Authorization Application for ...
Reactive Oxygen Species Are Your Friends! [Published In the Pipeline - Jan 11 2013] The line under James Watson's name reads, of course, "Co-discoverer of DNA. Nobel Prize". But it could also read "Provocateur", since he's been pretty good at that over the years. He seems to have the right personality for it - both The Double Helix ...
Morphotek farletuzumab Phase III study fails to... [Published PBR - News - Jan 11 2013] Morphotek, a wholly-owned subsidiary of Eisai, has reported that farletuzumab in combination with carboplatin and a taxane failed to meet the primary endpoint of progression-free survival (PFS) in Phase III study. ...

Press Releases

sort by: Date \| Relevance
ImmunoGen, Inc. Announces FDA Approval of Kadcy... [Published Business Wire Health News - Feb 22 2013]
FDA Approves Genentech’s Kadcyla (Ado-Trastuzum... [Published EON Science - Feb 22 2013]
FDA Approves Genentech’s Kadcyla (Ado-Trastuzum... [Published Business Wire Health News - Feb 22 2013]
Morphotek Announces Top-Line Results of a Phase... [Published PR Newswire: Health - Jan 10 2013]
Immunovative Announces Registration of Its Phas... [Published Marketwire - Breaking News Releases - Dec 17 2012]